United Therapeutics Corporation Common Stock Earnings Dividend
Earnings Summary
Revenue | $783.3Mn |
Net Profits | $333Mn |
Net Profit Margins | 42.51% |
United Therapeutics Corporation Common Stock’s revenue fell -1.92% since last year same period to $783.3Mn in the Q2 2026. On a quarterly growth basis, United Therapeutics Corporation Common Stock has generated 0.23% jump in its revenue since last 3-months.
United Therapeutics Corporation Common Stock’s net profit jumped 7.59% since last year same period to $333Mn in the Q2 2026. On a quarterly growth basis, United Therapeutics Corporation Common Stock has generated 21.13% jump in its net profits since last 3-months.
United Therapeutics Corporation Common Stock’s net profit margin jumped 9.69% since last year same period to 42.51% in the Q2 2026. On a quarterly growth basis, United Therapeutics Corporation Common Stock has generated 20.86% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | 6.38 |
EPS Estimate Current Year | 6.38 |
United Therapeutics Corporation Common Stock’s earning per share (EPS) estimates for the current quarter stand at 6.38 - a -6.45% fall from last quarter’s estimates.
United Therapeutics Corporation Common Stock’s earning per share (EPS) estimates for the current year stand at 6.38.
Key Ratios
Earning Per Share (EPS) | 7.27 |
United Therapeutics Corporation Common Stock’s earning per share (EPS) jumped 13.42% since last year same period to 7.27 in the Q2 2026. This indicates that the United Therapeutics Corporation Common Stock has generated 13.42% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-08-05 | 6.82 | 7.27 | 6.6% |
2026-05-06 | 6.86 | 5.82 | -15.16% |
